Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.40), $0.09 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.78 million versus the consensus estimate of $12.72 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.